Business
China Resources Sanjiu Medical & Pharmaceutical Co: 2025 revenue up 14.43%, net profit up 1.58%, with robust R&D and major acquisition
China Resources Sanjiu Medical & Pharmaceutical Co: 2025 revenue up 14.43%, net profit up 1.58%, with robust R&D and major acquisition
About this update from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A
Revenue grew 14.43% to RMB 31.60 billion and net profit rose 1.58% to RMB 3.42 billion, driven by strong CHC and prescription drug segments, major R&D investment, and the acquisition of Tian Shi Li. Dividend payout ratio reached 50.59% for 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.